🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05879835
Recruiting Not applicable

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835 · tracked via the Priya Life Science USA tracker
Sponsor
SterileCare Inc.
Phase
Not applicable
Started
2024-06-21
Last updated
2026-06-04

Condition(s) studied

Pediatric Intestinal Failure

Investigational drug(s) / intervention(s)

KiteLock 4% Sterile Catheter Lock SolutionHeparin Lock Solution

KiteLock 4% Sterile Catheter Lock Solution: KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.

Heparin Lock Solution: Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.

Study summary

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

Eligibility

Sex
ALL
Min age
4 Weeks
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients managed by the intestinal rehabilitation program at one of the participating centers. 2. Diagnosis of intestinal failure defined as need for PN support for \>60 days in previous 74 days for primary intestinal disease (short bowel syndrome, primary motility disorder, mucosal enteropathy). 3. Expectation of the treating physician that the patient will require PN for at least 6 months following enrollment. 4. Age less than 18 years at diagnosis but greater than 4 weeks chronological age or 40 weeks estimated gestational age, whichever is greater. 5. Stable TPN cycling (4 hours off TPN minimum per day) enabling home TPN management 6. Presence of a tunneled central venous catheter (CVC), port-a-catheter, or peripherally inserted central catheter (PICC). 7. Clinical stability for at least 4 weeks and no acute medical comorbidities. 8. A minimum dwell time of 4 consecutive hours daily. 9. Care provider willing to provide informed consent to participate in the trial and willing to comply with randomization and study protocol. Exclusion Criteria: 1. A temporary CVC (jugular or femoral) or peripheral catheter. 2. Patients receiving long-term PN, but not due to a primary intestinal disorder (i.e., oncology patients or premature neonates on PN due to intestinal immaturity). 3. Known hypersensitivity, allergy, or reaction to EDTA. 4. Pregnancy or nursing mother. 5. Participation in another investigational device or drug trial within 30 days prior to enrollment (unless approved by the principal investigators of the trial). 6. Severe coagulopathy (platelets \<50,000, or INR \> 1.5). 7. Diagnosis of immunodeficiency disorder. 8. Unstable medical condition requiring hospital admission 9. Received antibiotic therapy for CLABSI within last 14 days.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Boston Children's Hospital Boston Massachusetts Recruiting
University of Nebraska Medical Center Omaha Nebraska Not Yet Recruiting
Nyph/Cumc New York New York Recruiting
Duke University Medical Center Durham North Carolina Recruiting
Cincinnati Children's Hospital Medical Center Cincinnati Ohio Recruiting
Nationwide Children's Hospital Columbus Ohio Recruiting
Cook Children's Health Care System Fort Worth Texas Recruiting
Seattle Children's Hospital Seattle Washington Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05879835 on ClinicalTrials.gov ↗ ← All trials in the USA